Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Coformycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA known ✓ | P00813 | 5/20 | 1.00 |
| ▸ | AMPD3 | Q01432 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.67 |
| ▸ | AMPD2 | Q01433 | 6/20 | 0.51 |
| ▸ | ATIC | P31939 | 1/20 | 0.48 |
| ▸ | AMPD1 | P23109 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coformycin SCHEMBL11184406 | 1.00 | ADA (1.00) | ADAAMPD3ADORA3ADORA1ADORA2A | |
| SCHEMBL29823077 | 0.90 | ADA (0.82) | ADAAMPD3ADORA3ADORA1ADORA2A | |
| SCHEMBL29952186 | 0.82 | ADA (0.69) | ADAAMPD3ADORA3ADORA1ADORA2A | |
| Pentostatin SCHEMBL1649740 | 0.81 | ADA (1.00) | ADAAMPD3ADORA3ADORA1ADORA2A | |
| Pentostatin SCHEMBL2045053 | 0.81 | ADA (1.00) | ADAAMPD3ADORA3ADORA1ADORA2A | |
| Pentostatin SCHEMBL14031902 | 0.81 | ADA (1.00) | ADAAMPD3ADORA3ADORA1ADORA2A | |
| Pentostatin SCHEMBL5549091 | 0.81 | ADA (1.00) | ADAAMPD3ADORA3ADORA1ADORA2A | |
| Pentostatin SCHEMBL2818 | 0.81 | ADA (1.00) | ADAAMPD3ADORA3ADORA1ADORA2A | |
| SCHEMBL29885458 | 0.77 | ADA (0.63) | ADAAMPD3ADORA3ADORA1ATIC | |
| Pentostatin SCHEMBL28886873 | 0.76 | ADA (0.90) | ADAAMPD3ADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | IDENIX PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | IDENIX PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008082602-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | NTPCR, PNP, TYMP | ADA 215/4885AMPD3 659/4885ADORA3 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.